Please wait while the formulary information is being retrieved.
Drug overview for GENVISC 850 (hyaluronate sodium):
Generic name: HYALURONATE SODIUM (HYE-al-ure-ON-ate)
Drug class: Visco-Elastics, Intra-articular
Therapeutic class: Locomotor System
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: HYALURONATE SODIUM (HYE-al-ure-ON-ate)
Drug class: Visco-Elastics, Intra-articular
Therapeutic class: Locomotor System
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
GENVISC 850 25 MG/2.5 ML SYR
The following indications for GENVISC 850 (hyaluronate sodium) have been approved by the FDA:
Indications:
Osteoarthritis of the knee
Professional Synonyms:
Degenerative arthritis of the knee
Degenerative joint disease of the knee
DJD of the knee
Hypertrophic arthritis of the knee
OA of the knee
Osteoarthrosis of the knee
Indications:
Osteoarthritis of the knee
Professional Synonyms:
Degenerative arthritis of the knee
Degenerative joint disease of the knee
DJD of the knee
Hypertrophic arthritis of the knee
OA of the knee
Osteoarthrosis of the knee
The following dosing information is available for GENVISC 850 (hyaluronate sodium):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| GENVISC 850 25 MG/2.5 ML SYR | Maintenance | Adults inject 2 milliliters (20 mg) into the affected knee by intra-articular route every 7 days for 5 weeks |
No generic dosing information available.
The following drug interaction information is available for GENVISC 850 (hyaluronate sodium):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for GENVISC 850 (hyaluronate sodium):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Infection of bone, joint, skin, or soft tissue of knee |
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for GENVISC 850 (hyaluronate sodium):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 4 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Anaphylaxis Drug fever Skin rash Urticaria |
| Rare/Very Rare |
|---|
| None. |
There are 11 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Anorexia Diarrhea Ecchymosis Gastrointestinal irritation Headache disorder Injection site sequelae Knee inflammation Nausea Pruritus of skin Vomiting |
None. |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for GENVISC 850 (hyaluronate sodium):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
| Drug Name | Excretion Potential | Effect on Infant | Notes |
|---|---|---|---|
| Hyaluronate Sodium | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Insufficient human data available |
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for GENVISC 850 (hyaluronate sodium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for GENVISC 850 (hyaluronate sodium)'s list of indications:
| Osteoarthritis of the knee | |
| M17 | Osteoarthritis of knee |
| M17.0 | Bilateral primary osteoarthritis of knee |
| M17.1 | Unilateral primary osteoarthritis of knee |
| M17.10 | Unilateral primary osteoarthritis, unspecified knee |
| M17.11 | Unilateral primary osteoarthritis, right knee |
| M17.12 | Unilateral primary osteoarthritis, left knee |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee |
| M17.3 | Unilateral post-traumatic osteoarthritis of knee |
| M17.30 | Unilateral post-traumatic osteoarthritis, unspecified knee |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee |
| M17.4 | Other bilateral secondary osteoarthritis of knee |
| M17.5 | Other unilateral secondary osteoarthritis of knee |
| M17.9 | Osteoarthritis of knee, unspecified |
Formulary Reference Tool